Inclusion Criteria:

- Sex: male or female

- Age: from 18 to 80 years

- Histology: gastric cancer

- Clinical stage: stage IV

- Karnofsky performance status: more than 50%

- Expected survival: more than 2 months

- Sex: male or female

- Laboratory tests results 7 days before the start of treatment:

- White blood cells: more than 3.0 × 109/L

- Platelets: more than 100 × 109/L

- Neutrophils: more than 1.5 × 109/L

- Hemoglobin: more than 80g/L

- Serum glutamate pyruvate transaminase: less than 2.5 folds of the upper normal
limit (ULN)

- Serum glutamic-oxal (o) acetic transaminase: less than 2.5 × ULN

- Serum bilirubin: less than 1.25 × ULN

- Serum creatinine: less than 1.25 × ULN

- Pregnancy test: the test of women of child-bearing period must be negative 7 days
before the start of treatment

- Contraception: male and female subjects of child-bearing period must adopt a reliable
method of contraception before entry into this study until 30 days after stopping
this study

- Informed consent: subject must have the ability to understand and voluntarily sign a
written informed consent

Exclusion Criteria:

- History of neoplasms: other neoplasms

- Medical history: mental disease, or congestive heart failure, or severe coronary
artery disease, or cardiac arrhythmias, or concomitant corticosteroid therapy

- Metastasis: clinical symptoms of brain metastasis

- Other clinical trial: the subject received other clinical trial before this study

- Laboratory tests: the serum test of human immunodeficiency virus, or hepatitis B
virus, or hepatitis C virus was positive

- Woman: pregnant or lactating women

- Compliance: poor compliance